GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Cash Ratio

Cleo Diagnostics (ASX:COV) Cash Ratio : 50.79 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Cleo Diagnostics's Cash Ratio for the quarter that ended in Dec. 2023 was 50.79.

Cleo Diagnostics has a Cash Ratio of 50.79. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Cleo Diagnostics's Cash Ratio or its related term are showing as below:

ASX:COV' s Cash Ratio Range Over the Past 10 Years
Min: 0.12   Med: 0.49   Max: 50.79
Current: 50.79

During the past 1 years, Cleo Diagnostics's highest Cash Ratio was 50.79. The lowest was 0.12. And the median was 0.49.

ASX:COV's Cash Ratio is ranked better than
99.63% of 820 companies
in the Medical Devices & Instruments industry
Industry Median: 1.235 vs ASX:COV: 50.79

Cleo Diagnostics Cash Ratio Historical Data

The historical data trend for Cleo Diagnostics's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Cash Ratio Chart

Cleo Diagnostics Annual Data
Trend Jun23
Cash Ratio
0.12

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23
Cash Ratio 0.49 0.12 50.79

Competitive Comparison of Cleo Diagnostics's Cash Ratio

For the Medical Devices subindustry, Cleo Diagnostics's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cleo Diagnostics's Cash Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Cash Ratio falls into.



Cleo Diagnostics Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Cleo Diagnostics's Cash Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Cash Ratio (A: Jun. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=0.24/2.02
=0.12

Cleo Diagnostics's Cash Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash Ratio (Q: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=10.108/0.199
=50.79

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cleo Diagnostics  (ASX:COV) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Cleo Diagnostics Cash Ratio Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleo Diagnostics (ASX:COV) Business Description

Traded in Other Exchanges
N/A
Address
480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines